Long-term efficacy and safety of fourth-line multikinase inhibitor treatment with lenvatinib in a young papillary thyroid carcinoma patient

Lenvatinib, a multikinase inhibitor, is approved for the treatment of patients with radioiodine-refractory metastatic thyroid cancer on the basis of a Phase III, prospective, double-blind, randomized, placebo-controlled trial that showed longer progression-free survival in the drug-treated arm. Here...

Descripción completa

Detalles Bibliográficos
Autores principales: Morelli, S., Puxeddu, E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Just Medical Media Limited 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5699105/
https://www.ncbi.nlm.nih.gov/pubmed/29167691
http://dx.doi.org/10.7573/dic.212310

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5699105/
https://www.ncbi.nlm.nih.gov/pubmed/29167691
http://dx.doi.org/10.7573/dic.212310

Ejemplares similares